禾元生物 (688765)

1. Key Indicators

• Total Shares(W): 35750.00
• Circulating A-Shares(W): 4097.88
• Earnings Per Share(RMB): -0.4524
• Net Assets Per Share(RMB): 1.8500
• Operating Revenue(W RMB): 1966.08
• Total Profit(W RMB): -12127.09
• **Net Profit Attributable to Parent(W RMB) **: -12127.09
• Net Profit Growth Rate(%): -8.44
• Weighted Return on Equity(%): -22.4300
• Operating Cash Flow Per Share(RMB): -0.4400
• Undistributed Profit Per Share(RMB): -3.6286
• Capital Reserve Per Share(RMB): 4.4825

---

2. Main Business

The main business covers:

• Research, development, production, and commercialization of plant molecular medicine

---

3. Company Basic Information

• Company Name: Wuhan Oryzogen Biotech Co., Ltd.
• Listing Date: 2025-10-28
• Industry: Pharmaceutical Manufacturing
• Address: No. 268 Shendun 5th Road, East Lake High-tech Development Zone, Wuhan, Hubei Province
• Website: https://www.oryzogen.com
• Company Profile: On November 10, 2014, the shareholders' meeting of Oryzogen Co., Ltd. resolved to approve the overall transformation of the limited company into a joint stock company, agreeing to set the audit and evaluation base date as October 31, 2014. On November 25, 2014, Zhonghuan Haihua Certified Public Accountants Co., Ltd. issued an "Audit Report," stating that as of October 31, 2014, the net asset value of Oryzogen Co., Ltd. was 81.5414 million yuan. On November 25, 2014, Hubei Zhonglian Asset Appraisal Co., Ltd. issued an "Asset Appraisal Report," stating that as of the appraisal base date of October 31, 2014, the net asset book value of Oryzogen Co., Ltd. was 81.5414 million yuan, and the net asset appraisal result was 82.4924 million yuan. On November 26, 2014, all shareholders of Oryzogen Co., Ltd. signed the "Sponsorship Agreement for Wuhan Oryzogen Biotech Co., Ltd.," unanimously agreeing to the overall transformation of Oryzogen Co., Ltd. into a joint stock company. All sponsors converted the audited net assets of Oryzogen Co., Ltd., amounting to 81.5414 million yuan, into 38 million shares at a ratio of 2.145827563:1. The original shareholders of Oryzogen Co., Ltd., as sponsors, subscribed to the shares with the net assets corresponding to their respective shareholding ratios in Oryzogen Co., Ltd. On November 26, 2014, the company held its founding meeting and first shareholders' meeting, reviewing and passing relevant proposals such as the "Proposal on Approving the Overall Transformation of Wuhan Oryzogen Biotech Co., Ltd. into Wuhan Oryzogen Biotech Co., Ltd. by Converting the Audited Net Assets of Wuhan Oryzogen Biotech Co., Ltd.," agreeing to the overall transformation of Oryzogen Co., Ltd. into a joint stock company. On November 26, 2014, Zhonghuan Haihua Certified Public Accountants Co., Ltd. issued a "Capital Verification Report," confirming that as of October 31, 2014, the company had received a registered capital of 38 million yuan from all sponsors. On December 19, 2014, the Wuhan Administration for Industry and Commerce issued the "Business License" to the company. Unified Social Credit Code: 91420100792447416G.

---

4. Top 10 Circulating Shareholders

Rank	Institution Name	Institution Type	Shares Held (W)	Percentage Held (%)
No Data Available	No Data Available	No Data Available	No Data Available	No Data Available

---

5. Concept Sectors

• Secondary New Stock
• Innovative Drugs
• Margin Trading and Securities Lending
• Consecutive Losses
• High-Price Stock
• Near-Term Secondary New Stock
• Increased Margin Financing
• Yesterday's Top Performer
• Sci-Tech Innovation Board Secondary New Stock
• Science and Technology Innovation Layer

---

Remarks

• Data update date: 2025-11-02
• Data source: Public market information